Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription
- 71 Downloads
Enhanced removal of cisplatin-DNA adducts has been reported as one of main causesof cell resistance to cisplatin. This particular resistance mechanism may be circumvented by platinum complexes that bind differently to DNA. One line of work is focussed on trans platinum complexes, some of which exhibit antitumour activity similar to or even higher than that of their cis counterparts.
We synthesised new trans platinum complexes, trans-[PtCl2(cyclohexylamine) (dimethylamine)] and trans-[PtCl2(OH)2(cyclohexylamine) (dimethylamine)], previously evaluated as cytotoxic agents towards different cancer and normal cell lines. These trans platinum compounds were highly effective against a panel of tumoral cell lines either sensitive to or with acquired resistance to cisplatin.
In the present work we examined the mechanisms induced by these compounds to cause tumour cells toxicity. We have found that these compounds induced a complete blockade at the S phase of the cell cycle inhibiting total mRNA transcription and precluding p53 activation.
In contrast to other DNA-damaging agents, these compounds do not induce senescence-associated permanent arrest. Furthermore, only a small percentage of these cells enter into apoptosis, with most of the population dying by a necrosis-like mechanism.
Key wordsAntitumour drugs Platinum anticancer drugs Transplatin Cytotoxic activity Cell cycle
Unable to display preview. Download preview PDF.
- 1.Lippert B (1999) 30 years of cisplatin — chemistry and biochemistry of a leading anticancer drug. Verlag HCA, BaselGoogle Scholar
- 2.Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59[Suppl]:4–9Google Scholar
- 3.Kelland LR, Farrell N (2000). Platinum-based drugs in cancer therapy. In: Teicher BA (ed.) Cancer drug discovery and development. Humana Press, Clifton, UKGoogle Scholar
- 10.Farrell N, Kelland LR, Roberts JD, Van Beusichem M (1992) Activation of the trans geometry in platinum antitumor complexes. A survey of the cytotoxicity of trans complexes containing planar ligands in Murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52:5065–5072PubMedGoogle Scholar
- 18.Van Beusichem M, Farrell N (1992) Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterisation and biological activity of complexes with planar ligands pyridine, N-methylimidazole, thiazole and quinoline. The crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II). Inorg Chem 31:634–639CrossRefGoogle Scholar
- 19.Farrell N (1996) Current status of structure-activity relationships of platinum anticancer drugs. Activation of the trans geometry. Metal Ions Biol Sys 32:603–639Google Scholar
- 21.Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Progr Nucleic Acid Res Mol Biol 71:1–68Google Scholar
- 24.Bierbach U, Qu Y, Hambley TW et al (1999) Synthesis, structure, biological activity and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3)L] (L = planar nitrogen base). Effect of L and cis/trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg Chem 38:3535–3542PubMedCrossRefGoogle Scholar
- 26.Barnard CFJ, Raynaud FY, Kelland LR (1999) In: Clarke MJ, Sadler PJ (eds) Metallopharmaceuticals I: DNA Interactions. Springer, Berlin, pp. 45Google Scholar
- 35.Carnero A, Blanco C, Blanco F et al (2003) Exploring cellular senescence as a tumor suppressor mechanism. Revista de Oncologia 5:249–265Google Scholar